4.8.24
News
3.21.24
Accent Therapeutics to Present Data Supporting DHX9 and KIF18A as Compelling Therapeutic Targets at American Association for Cancer Research (AACR) Annual Meeting 2024
1.23.24
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
10.10.23
Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium
9.21.23
Accent Therapeutics Bolsters Leadership Team with Key Executive Hires
4.16.23
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
4.6.23
Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
6.4.20